CYTK

Over the past six months, Cytokinetics' stock has experienced significant events. The stock price has shown a substantial increase over the past year, with a 52-week range between $29.31 and $80.20. The FDA approved MYQORZO in December 2025, followed by its U.S. commercial launch in January 2026, and the European Commission (EC) also approved MYQORZO. In May 2026, positive topline results from the ACACIA-HCM trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) were announced, contributing to a stock surge. Cytokinetics raised $760 million in a stock offering in May 2026. In April and May 2026, some senior executives sold shares, though they still retain sizable stakes. The company reported its first-quarter 2026 financial results in May 2026, highlighting strong demand for MYQORZO in its initial U.S. launch.